Owners, management and financials
CVR: 42038660
Previous names: Vaccibody Denmark A/S
DKK 31,839,001
Gross profit
Net result: DKK 1,347,127
Nykode Therapeutics ASA (100%)
CVR · view owners
Michael Thyrring Engsig
Board: Louise Stubbe (chair) and 2 members
CVR · view management
Active
Founded 8 January 2021
CVR · view overview
11 employees
CVR · 2026
Name registered: Nykode Therapeutics Denmark A/S
CVR · 20/12/2021
View the full event history
Nykode Therapeutics Denmark A/S is a Danish company of the type Aktieselskab based in Kongens Lyngby, founded in 2021. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The company was previously named Vaccibody Denmark A/S. The management consists of Michael Thyrring Engsig. The board consists of Louise Stubbe (chair), Harald Gurvin and Michael Thyrring Engsig. The company is owned by Nykode Therapeutics ASA. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK 31,839,001 and a net result of DKK 1,347,127 compared with DKK 156,959 the year before. Equity in the 2025 report amounted to DKK 6,862,099.
Source: annual report 2025, Danish Business Authority
Nykode Therapeutics Denmark A/S demonstrates a positive financial trajectory, with gross profit increasing from 10.6 million DKK in 2021 to 31.8 million DKK in 2025, alongside a notable rise in profit from 578,082 DKK to 1.3 million DKK over the same period. The company's equity has also improved significantly, reaching 6.9 million DKK in 2025, indicating a strengthening financial position. However, the absence of revenue figures raises concerns about overall sales performance and market penetration. As a relatively new player in the business consulting industry, Nykode's growth in profit margins and equity suggests potential for future stability and expansion.
AI-generated summary · Generated 15/08/2026
Selskabets formål er at levere ledelsesmæssige, administrative og specialiserede tjenester inden for den biofarmaceutiske industri samt udøve anden virksomhed, der står i forbindelse hermed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 31.8 mio. | 1.3 mio. | 15.6 mio. | 6.9 mio. | 16 | |
| 202401/01/2024 – 31/12/2024 | 63.6 mio. | 157 t. | 20.4 mio. | 5.5 mio. | 31 | |
| 202301/01/2023 – 31/12/2023 | 52.9 mio. | 2.5 mio. | 20.5 mio. | 5.4 mio. | 31 | |
| 202201/01/2022 – 31/12/2022 | 38.6 mio. | 1.9 mio. | 14.8 mio. | 2.9 mio. | 23 | |
| 202108/01/2021 – 31/12/2021 | 10.6 mio. | 578 t. | 11 mio. | 978 t. | 7 |
Compared to 11.552 companies in Virksomhedsrådgivning og anden ledelsesrådgivning
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorThe CVR number of Nykode Therapeutics Denmark A/S is 42038660.
Nykode Therapeutics Denmark A/S is owned by Nykode Therapeutics ASA.
The management of Nykode Therapeutics Denmark A/S consists of Michael Thyrring Engsig.
The board of Nykode Therapeutics Denmark A/S consists of Louise Stubbe, Harald Gurvin and Michael Thyrring Engsig, with Louise Stubbe as chair.
In 2025, Nykode Therapeutics Denmark A/S reported a gross profit of DKK 31,839,001.
Nykode Therapeutics Denmark A/S had 11 employees in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Nykode Therapeutics Denmark A/S has published its annual report for 2025. Gross profit came to DKK 31,839,001, and the net result was DKK 1,347,127.
Nykode Therapeutics Denmark A/S has published its annual report for 2024. Gross profit came to DKK 63,552,511, and the net result was DKK 156,959.
Nykode Therapeutics Denmark A/S has published its annual report for 2023. Gross profit came to DKK 52,927,648, and the net result was DKK 2,484,505.
Nykode Therapeutics Denmark A/S has published its annual report for 2022. Gross profit came to DKK 38,639,042, and the net result was DKK 1,895,426.
As of August 15, 2022, Louise Stubbe has joined the board of directors of Nykode Therapeutics Denmark A/S.
As of August 15, 2022, Harald Gurvin has joined the board of directors of Nykode Therapeutics Denmark A/S.
As of August 15, 2022, Katrine Hovgaard Husum has left the board of directors of Nykode Therapeutics Denmark A/S.
As of August 15, 2022, Alf Gunnar Martin Nicklasson has left the board of directors of Nykode Therapeutics Denmark A/S.
Nykode Therapeutics Denmark A/S has published its annual report for 2021. Gross profit came to DKK 10,590,585, and the net result was DKK 578,082.
As of January 20, 2022, Alf Gunnar Martin Nicklasson has joined the board of directors of Nykode Therapeutics Denmark A/S.
As of January 20, 2022, Anders Tuv has left the board of directors of Nykode Therapeutics Denmark A/S.
On December 20, 2021, the company changed its name from Vaccibody Denmark A/S to Nykode Therapeutics Denmark A/S.
As of April 21, 2021, Katrine Hovgaard Husum has joined the board of directors of Nykode Therapeutics Denmark A/S.
As of April 21, 2021, Lars Dencker Nielsen has left the board of directors of Nykode Therapeutics Denmark A/S.
As of January 8, 2021, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Nykode Therapeutics Denmark A/S.
As of January 8, 2021, Lars Dencker Nielsen has joined the board of directors of Nykode Therapeutics Denmark A/S.
As of January 8, 2021, Michael Thyrring Engsig has joined the board of directors of Nykode Therapeutics Denmark A/S.
As of January 8, 2021, Anders Tuv has joined the board of directors of Nykode Therapeutics Denmark A/S.
As of January 8, 2021, Michael Thyrring Engsig is registered as director of Nykode Therapeutics Denmark A/S.
As of January 8, 2021, is registered as an owner of Nykode Therapeutics Denmark A/S with an ownership share of 100%.
Nykode Therapeutics Denmark A/S was founded on January 8, 2021.
Companies in the same industry and area
CVR 36151609
CVR 45914682
CVR 25998189
CVR 25813294
CVR 43237179
